As the buzz around #AI in healthcare grows, let's not forget that patient care is at the heart of it all. Check out Andre Esteva, PhD and his insights on how #ArteraAI can help ease the stress patients face when deciding on the best treatment option for them. bit.ly/3XUAcd9"

ICYMI: The #ArteraAI Prostate Test has expanded to inform #activesurveillance decisions for lower-risk #prostatecancer patients, in a mission to "empower all those delivering cancer care". ➡️ Read more from Urology Times: urologytimes.com/view/arteraai-…

#ArteraAI is honored to be named a Finalist in the 2024 Digital Health Hub Foundation Awards! We've been selected for Best AI Healthcare Win, from among thousands of submissions globally. We are proud to be advancing innovation in healthcare!

Artera is excited to participate in #ASTRO24! Don't miss the oral presentations from Yang Song of University of Maryland, Baltimore and Philip Sutera of Johns Hopkins University, Oct 2 at 8:00 AM and 8:10 AM ET! #ArteraOnTheGo #CancerTreatment #ProstateCancer

Hola, Dominican Republic! Andre Esteva, PhD and Peter Wood from #ArteraAI will be joining CorePlus and meeting with Confederación Americana de Urología (CAU). We are excited to share how our #MMAI platform is impacting #prostatecancer treatment decision making.

The Artera team had a great time at #ASTRO2024! We met with a ton of folks, discussing the science behind the #ArteraAI Prostate Test, and presenting new research on how AI can inform treatment decisions for omCSPC - an early stage of metastatic #prostatecancer.

It's time for another tech blog! Learn more about the behind-the-scenes work of Artera engineer, Sufiyan Ghori, how he deals with network conflicts and some best practices to follow to avoid them in the first place. heyor.ca/xnWUbE #AWS #GitHub #AIinfrastructure

Progress developing pathology foundation models has been incredible. Luminaries like Faisal Mahmood Naoto Usuyama Richard J. Chen Nicolò Fusi Neil Tenenholtz, Andrew H. Song, Rahul G. Krishnan, Alexandre Filiot, Eric Zimmermann, Tong Ding, and many others have advanced the state-of-the-art rapidly.

In JCO Precision Oncology, Dr. Jonathan Tward et al. highlight how #ArteraAI’s multimodal #AI models reclassify risk categories, improving accuracy over current #NCCN methods - an approach that supports better decision-making and personalized care: heyor.ca/jjvPiZ

We're excited to collaborate with Tempus and increase access to the #ArteraAI Prostate Test. It's an honor to be selected by a pioneer in #precisionmedicine to be their exclusive provider of #digitalpathology tests for #prostatecancer. To learn more: heyor.ca/G67drv

The #ArteraAI team had a great time at the Grand Rounds Urology #IPCU2025 event in Colorado, where leading experts gathered to discuss the latest advancements and best practices in the prevention and treatment of #prostatecancer.

That’s a wrap on ASCO #GU25! 🎉 The #ArteraAI team had an incredible time connecting with colleagues, sharing insights, and advancing the conversation around #precisionmedicine in #prostatecancer.

We're excited to attend the Mayo Clinic Urology Review in Puerto Rico this month! Stop by to meet with #ArteraAI's Paul Hawkinson and John Benton to learn more about how the ArteraAI Prostate Test is helping patients with #prostatecancer. heyor.ca/YJ7VMj

It's not easy to deploy clinical #AImodels globally, due to regulatory & compliance issues. In this #techblog, we explain our 4-step process for international deployment and how we partnered with Union_ai as we expanded into Australia. heyor.ca/80sHiJ

We’re proud to have Marc Benioff on Artera’s board, helping shape how AI transforms precision medicine. Check out his latest interview on the future of AI in business via Chief Executive: heyor.ca/mpLN8u #AIinHealthcare #MarcBenioff #Leadership

Just announced at #ASCO25: The ArteraAI Prostate Test is now enhanced for high-risk localized prostate cancer—helping identify which patients benefit from abiraterone and who may safely avoid added toxicity, cost, and complexity: itnonline.com/content/prosta…

We’re proud to wear blue in support of #MensHealthWeek and #WearBlueDay. With prostate cancer ranking as the second most common cancer in U.S. men according to American Cancer Society, it’s a powerful reminder of the value of early detection, awareness, and personalized care.

ICYMI: Prof. Nick James of The ICR joined The Uromigos Podcast to share new #ASCO25 data on the ArteraAI Prostate Test—showing how AI can identify which high-risk patients truly benefit from adding abiraterone to ADT: bit.ly/artera-uromigos

Prostate cancer affects everyone differently. AI can help doctors spot patterns in biopsy images to guide decisions, like whether short-term ADT with radiation may help. Because cancer is personal, therapy should be too. Learn more in this summary of our predictive validation:

How is AI transforming cancer treatment? Listen to the conversation on how AI-powered tools are helping personalize care for patients: heyor.ca/uP2kp0 #AIinHealthcare #ProstateCancer #PrecisionMedicine #ArteraAI